Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid osmolarity and volume.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
20 mEq potassium chloride in 0.9% sodium chloride, intravenous infusion at a rate not exceeding 10-20 mEq/hour; maximum 150 mEq/day.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function, reflecting rapid renal clearance. In renal impairment, half-life is significantly prolonged, necessitating dose adjustment.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal excretion accounts for approximately 90% of potassium elimination; the remaining 10% is eliminated via the gastrointestinal tract. Minor biliary/fecal loss is negligible in normal physiology.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."